Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betaine for MASH
NCT07276204Phase 2Not yet recruiting
- Sponsor
- Southern California Institute for Research and Education
- Start
- Mar 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Betaine + SOC with Placebo + SOC (2 arms). Primary endpoint: Non-Invasive Steatohepatitis 2+ Score at 24 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
betaine
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07276204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07276204.